Dose Optimization of Linezolid in Critically Ill Patients Based on A Population Pharmacokinetics Model: A Two-center Prospective Interventional Study

Lu Shi,Ying Zhang,Lufen Duan,Lifeng Huang,Jingjing Li,Jian Lu,Zhiwei Zhuang,Yunlong Yuan,Zongtai Feng,Jiantong Sun,Xin Liu,Qin Zhou,Hongzhi Xue,Jinhui Xu,Lian Tang
DOI: https://doi.org/10.1016/j.ijantimicag.2023.106881
IF: 15.441
2023-06-09
International Journal of Antimicrobial Agents
Abstract:Objective We aimed to evaluate the intervention effect of clinical pharmacist-mediated optimization of a linezolid regimen using a population pharmacokinetics (PPK) model. Methods Patients treated with linezolid in two medical centers from January 2020 to June 2021 were retrospectively included in the control group; in contrast, those treated from July 2021 to June 2022 were prospectively enrolled in the intervention group. Clinical pharmacists optimized the dosage regimen according to the published linezolid PPK model in the intervention group. The interrupted times series approach was used to analyze the data. The incidence of linezolid-induced thrombocytopenia (LIT), target attainment of pharmacokinetic/pharmacodynamic parameters, and other adverse drug reactions (ADRs) were compared between the two groups. Results We enrolled 77 and 103 patients in the control and intervention groups. The intervention group had a lower incidence of LIT and other ADRs than the control group (10.7% vs . 23.4%, P =0.002; 1.0% vs. 7.8%, P =0.027). The intervention group exhibited a considerably lower trough concentration (C min ) and area under the curve divided by the minimum inhibitory concentration (AUC 24 /MIC) than the control group ( P =0.001; P <0.001). C min and AUC 24 /MIC rates within the target range were substantially higher in the intervention group than in the control group (49.6% vs. 20.0%, adjusted P <0.05; 48.1% vs. 25.6%, adjusted P <0.05). Conclusion Interventions by clinical pharmacists reduced the incidence of LIT and other ADRs. Implementation of model-informed precision dosing for linezolid markedly increased the C min and AUC 24 /MIC rates within the target range. We recommend MIPD-guided linezolid dose reduction for patients with renal impairment.
pharmacology & pharmacy,infectious diseases,microbiology
What problem does this paper attempt to address?